

Table of Contents – Overview

Preface	V
1 Products of Nature: What is Patentable in the EPO (compounds, stem cells, plants, etc.) <i>Dr. Christian Schlörb</i>	1
2 The Person Skilled in the Art <i>Dr. Andreas Heiseke</i>	21
3 The Principles Applied by the Technical Boards in Assessing the Disclosure of a Document and Their Implications <i>Oswin Ridderbusch</i>	35
4 The Principles Applied by the Technical Boards in Claim Construction <i>Oswin Ridderbusch</i>	69
5 Plausibility as a Means to Assess Quid Pro Quo <i>Dr. Hans-Rainer Jaenichen</i>	91
6 The Principles of Patenting Medical and Diagnostic Uses <i>Oswin Ridderbusch</i>	153
7 Patenting Nucleic Acid Inventions <i>Dr. Hans-Rainer Jaenichen</i>	243
8 Patenting Protein Inventions <i>Dr. Hans-Rainer Jaenichen</i>	439
9 Patenting Antibody Inventions <i>Dr. Jürgen Meier</i>	582
10 Patenting Microorganisms and Fermentation Technologies <i>Dr. Stefan Müller</i>	672
11 Patenting Viruses <i>Dr. Andreas Heiseke</i>	802
12 Patenting Stem Cells and Cell-based Therapeutics <i>Dr. Jürgen Meier</i>	914
13 Patenting Nucleic Acid Amplification Technologies <i>Richard Enmon, Ph.D., J.D.</i>	942
14 Patenting Genome Editing Technologies: Crispr et al. <i>Dr. Andreas Heiseke</i>	997
15 Patenting Next Generation Sequencing Technologies <i>Dr. Florian Grasser</i>	1023
16 Patenting Personalized Medicines and Companion Diagnostics <i>Dr. Christian Schlörb</i>	1055

17	Patenting Plants and Animals	
	<i>Dr. Olaf Malek</i>	1067
18	Priority – Hurdles of Same Subject Matter and Legal Entitlement	
	<i>Dr. Olaf Malek</i>	1174
19	Deposit	
	<i>Dr. Stefan Müller</i>	1225
20	How to draft a European Patent Application and Claims	
	<i>Dr. Philipp Marchand</i>	1243
21	A Brief Introduction to Supplementary Protection Certificates	
	<i>Oswin Ridderbusch</i>	1259
22	Biotech Litigation In Germany And The Netherlands, Perspectives Arising From The Implementation Of The UPC	
	<i>Daan de Lange, Dr. Kai Rüting</i>	1267
	Decisions of the EPO	1325
	Index	1403

Table of Contents – Detailed

Preface	V
1. Products of Nature: What is Patentable in the EPO (compounds, stem cells, plants, etc.)	
<i>Dr. Christian Schlörb</i>	1
1.1 The Legal Framework: Patentable Inventions and Exceptions	1
1.2 Patentable Biotechnological Inventions.	2
1.3 The patenting of human DNA is not intrinsically unethical	5
1.3.1 T 1213/05, “Breast and ovarian cancer/UNIVERSITY OF UTAH”, EPB1 705 902	5
1.4 Compounds and Discoveries, Industrial Applicability.	7
1.4.1 Recombinant heterodimeric receptors are no discovery when industrially applicable: T 338/00, “Multimeric receptors/SALK INSTITUTE”, EP-B1 619 842.	7
1.4.2 Industrial applicability of newly identified polypeptides: T 870/04, “BDP1 Phosphatase/MAX-PLANCK”, EP-A1 914 425	7
1.4.3 Industrial applicability: T 604/04, “PF4A receptors/GENENTECH”, EPB1 577 752	9
1.4.4 Industrial Applicability: T 898/05, “Hematopoietic receptors/ZYMOGENETICS”, EP-B1 910 635	10
1.4.5 Industrial Applicability: T 641/05, “GPCR-like receptor/PHARMACIA”, EP-A1 1 238 076	12
1.4.6 Industrial Applicability: T 1452/06, “Serine protease/BAYER”, EP-A1 1 309 676	12
1.4.7 Industrial Applicability: T 1165/06, “IL-17 related polypeptide/SCHE-RING”, EP-A1 1 141 297	13
1.4.8 DNA Sequences Isolated from Natural Sources Are no Discovery, Industrial Applicability: T 1213/05, “Breast and ovarian cancer/UNIVERSITY OF UTAH”, EP-B1 705 902.	13
1.4.9 Industrial Applicability: T 1450/07, “TGFα-HII/HUMAN GENOME SCIENCES”, EP-B1 826 041	15
1.4.10 Industrial applicability: T 1540/07, “Cytokine receptor/HUMAN GENOME SCIENCES”, EP-A1 1 093 457	15
1.4.11 T 18/09, “Neutrokin/HUMAN GENOME SCIENCES”, EP-B1 939 804.	16
1.4.12 Industrial applicability of newly identified polypeptides: T 1109/10, “Industrial application/LEXICON” (March 13, 2014), EP-B1 1 461 425. . .	18
1.5 No invention: scheme, rule or method for performing a mental act or doing business	19
1.5.1 Mere mental act: T 758/12, “Selecting psychotropic medications/MAYO FOUNDATION”, EP-B1 2 046 996.	19
1.6 Inventions relating to bioinformatics	19
1.6.1 Mathematical methods: T 784/06, “Genotype determination/BECKMAN”, EPB1 0 736 107.	19
1.6.2 Mathematical methods: T 2070/07, “DNA Mixture Analysis/PERLIN”, EPB1 1 229 135.	20

2.	The Person Skilled in the Art	
	<i>Dr. Andreas Heiseke</i>	21
2.1	Who/what is the person skilled in the art?	21
2.2	The attitude of the person skilled in the art.	26
2.3	The common general knowledge of the person skilled in the art	29
3.	The Principles Applied by the Technical Boards in Assessing the Disclosure of a Document and Their Implications	
	<i>Oswin Ridderbusch</i>	35
3.1	A Uniform Concept of Disclosure	35
3.2	The Standard of Direct and Unambiguous Disclosure.	36
	3.2.1 Basic Principles.	36
	3.2.2 Implicit Disclosure	37
	3.2.3 Assessing the Disclosure of a Document as a Whole.	40
3.3	The Relevant Point in Time for Determining the Disclosure of a Document	40
3.4	Inherent Disclosure	41
3.5	Combinations Within a Document	53
	3.5.1 All Features Have to be Disclosed in a Single Embodiment	53
	3.5.2 The Two-List Principle: Selections from Multiple Lists of Alternatives	55
	3.5.3 Intermediate Generalizations	66
	3.5.4 Combinations of Numerical Ranges.	67
4.	The Principles Applied by the Technical Boards in Claim Construction	
	<i>Oswin Ridderbusch</i>	69
4.1	Different Approaches to Claim Construction: The Patent as its Own Dictionary versus Interpretation as a Means to Resolve Ambiguities.	69
4.2	The Mind Willing to Understand	72
4.3	The Relevance of Article 69 EPC for Claim Construction	75
4.4	Further Principles of Claim Construction.	85
	4.4.1 Claim Construction as a Point of Law	85
	4.4.2 Interpretation of Claims in the Broadest Technically Sensible Manner.	85
	4.4.3 Interpretation of Independent Claims in View of their Subordinate Dependent Claims	87
	4.4.4 Interpretation of Dependent Claims in View of their Superordinate Independent Claims	87
	4.4.5 Interpretation of Different Terms as Having Different Meanings	87
	4.4.6 Interpretation of the Terms “Comprising”, “Consisting of” and “Having”	88
	4.4.7 Admissible Means of Claim Construction	89
5.	Plausibility as a Means to Assess Quid Pro Quo	
	<i>Dr. Hans-Rainer Jaenichen</i>	91
5.1	Introduction.	91
5.2	T1329/04, “Factor-9/JOHNS HOPKINS” (June 28, 2005), EP-A1 678 101	94
5.3	T 18/09, “Neutrokin/HUMAN GENOME SCIENCES” (October 21, 2009), EP-B1 939 804.	96
5.4	Decisions denying plausibility	99
5.5	Decisions acknowledging plausibility	118
5.6	The Essence	144

6.	The Principles of Patenting Medical and Diagnostic Uses	
	<i>Oswin Ridderbusch</i>	153
6.1	Fundamentals of First and Second Medical Use Claims and the Available Claim Formats	153
6.1.1	Legal Basis for First and Second Medical Use Claims in the Purpose-Limited Product Format	153
6.1.2	Second Medical Use Claims in the Swiss-Type Format under the EPC1973	155
6.1.3	The Interpretation of Purpose-Limited Product Claims Depends on whether the EPC1973 or the EPC2000 is Applicable.	156
6.1.4	The Availability and Interpretation of Swiss-Type Claims under the EPC2000	159
6.1.5	Claiming Second Medical Uses in Both the Purpose-limited Product Format and the Swiss-type Format	160
6.2	Different Types of Second Medical Uses	163
6.2.1	All Specific Therapeutic Uses are Patentable under G 2/08.	163
6.2.2	The Definition of the Therapeutic Treatment in a Second Medical Use Claim	165
6.2.3	Treatment or Prevention of Specific Diseases	187
6.2.4	Treatment of Specific Patient Groups	193
6.2.5	Specific Routes of Administration.	203
6.2.6	Specific Dosage Regimens.	204
6.2.7	Specific Mechanisms of Action	205
6.2.8	Specific Contraindications	218
6.2.9	Specific Combination Therapies.	219
6.3	The Types of Products That Can Be Claimed in a Medical Use Claim	222
6.4	Inventive Step Considerations Regarding Medical Use Claims	226
6.5	Surgical and Diagnostic Use Inventions	236
7.	Patenting Nucleic Acid Inventions	
	<i>Dr. Hans-Rainer Jaenichen</i>	243
7.1	Some of the History of Patenting Nucleic Acids and Systems for Their Expression: Options and Limits	243
7.1.1	The Genentech polypeptide expression cases T 292/85, T 293/85 and T 794/94, EP-B1 1 929	243
7.1.2	T 19/90, “Onco-mouse/HARVARD”, and T 694/92, “Modifying plant cells/MYCOGEN”	246
7.1.3	T 301/87 and T 500/91, “Alpha-interferons/BIOGEN”	248
7.1.4	T 412/93, “Erythropoietin/AMGEN”	251
7.1.5	T 18/09, “Neutrokin/HUMAN GENOME SCIENCES”	254
7.1.6	T 923/92, “t-PA/GENENTECH”	256
7.1.7	T 1213/05, “Breast and ovarian cancer/UNIVERSITY OF UTAH”	260
7.2	Correction of sequence errors	266
7.3	Clarity	270
7.3.1	The clarity requirement for claims is set out in Article 84 EPC:	270
7.4	Enablement	273
7.4.1	General principles developed in biotech cases.	273
7.4.2	Principles developed in biotech cases on the enablement of nucleic acid sequence inventions	281

7.5	Novelty.	310
7.5.1	General principles developed in biotech cases.	310
7.5.2	Principles developed in biotech cases on the assessment of novelty of nucleic acid sequence inventions.	324
7.6	Inventive Step.	353
7.6.1	General principles and a summary of what has been developed in biotech cases on the assessment of inventive step of nucleic acid inventions	353
7.6.2	Biotech decisions on inventive step of nucleic acid inventions	363
7.6.3	Biotech decisions on inventive step of systems for the expression of DNA sequences	411
7.6.4	Biotech decisions on inventive step of plasmids	436
8.	Patenting Protein Inventions	
	<i>Dr. Hans-Rainer Jaenichen</i>	439
8.1	Clarity	439
8.1.1	Some General principles for the assessment of clarity of protein-related claims	439
8.1.2	Biotech decisions on the clarity of protein claims	439
8.2	Enablement	441
8.2.1	General principles for the assessment of enablement of protein-related claims	441
8.2.2	Biotech decisions on the enablement of protein inventions	442
8.3	Novelty.	480
8.3.1	General principles for the assessment of novelty of protein-related claims ...	480
8.3.2	Biotech decisions on the novelty of protein inventions	483
8.4	Inventive Step.	513
8.4.1	General principles for the assessment of inventive step of protein-related claims	513
8.4.2	Biotech decisions on inventive step of protein inventions	515
9.	Patenting Antibody Inventions	
	<i>Dr. Jürgen Meier</i>	582
9.1	General considerations on antibody patenting in the EPO	582
9.1.1	Allowable claims and formats	583
9.1.2	Antibody definitions by structural features	583
9.1.3	Antibodies definitions by functional features	584
9.1.4	Antibody definitions by combined structural and functional features.	586
9.2	Clarity	589
9.2.1	General considerations on clarity of antibody claims	589
9.2.2	Clarity of antibody specificities and/or affinities	589
9.2.3	Clarity of structural features of antibody claims	591
9.2.4	Clarity of functional features of antibody claims.	592
9.2.5	Clarity of the term antibody, of antibody formats and of antibody designations	593
9.2.6	Clarity of epitopes and/or antibody target structures	595
9.2.7	Clarity of “product-by-process” antibody claims, antibody-related diagnostic methods and medical use claims	596

9.3	Enablement	598
9.3.1	General considerations on enablement of antibody claims	598
9.3.2	Enablement of structural features of antibody claims	605
9.3.3	Enablement of functional features or combinations of structural and functional features	607
9.3.4	Enablement of epitopes, antigens and/or antibody target structures	612
9.3.5	Enablement of method/production claims	613
9.3.6	Enablement of medical/diagnostic use claims concerning antibodies	617
9.4	Novelty.	625
9.4.1	General considerations on novelty of antibody claims-“polyclonal” versus “monoclonal”	625
9.4.2	Novelty of structural features	625
9.4.3	Novelty of functional features.	628
9.4.4	Novelty by epitope, antigen and/or target and/or structures and forms	630
9.4.5	Novelty of product-by-process claims and of production processes per se.	631
9.4.6	Novelty of medical/diagnostic use of antibodies	634
9.5	Inventive Step.	636
9.5.1	General considerations on inventive step of antibody claims “polyclonal” versus “monoclonal” and the provision of “alternative (monoclonal) antibodies” versus “(monoclonal) antibodies with specific unexpected properties”	636
9.5.2	Inventive step of structural antibody features	643
9.5.3	Inventive step of functional features alone or in combinations with structural features – the requirement or the non-requirement of frameworks.	647
9.5.4	Inventive step of epitopes and/or target structures	654
9.5.5	Inventive step of methods for making, modifying and/or purifying antibodies/antibody constructs.	656
9.5.6	Inventive step of antibodies in medical uses	661
10.	Patenting Microorganisms and Fermentation Technologies <i>Dr. Stefan Müller</i>	672
10.1	Clarity	672
10.1.1	Principles established in biotech cases.	672
10.1.2	Biotech decisions on the clarity of microorganisms and fermentation technology inventions.	672
10.2	Enablement	690
10.2.1	Principles established in biotech cases.	690
10.2.2	Biotech decisions on enablement of microorganisms and fermentation technology inventions.	691
10.3	Novelty.	719
10.3.1	Principles established in biotech cases.	719
10.3.2	Biotech decisions on the novelty of microorganisms and fermentation technology inventions.	719
10.4	Inventive Step.	747
10.4.2	Biotech decisions on inventive step of microorganisms and fermentation technologies	747

11.	Patenting Viruses	
	<i>Dr. Andreas Heiseke</i>	802
11.1	Clarity	802
11.2	Enablement	809
11.3	Novelty.	837
11.4	Inventive Step.	854
12.	Patenting Stem Cells and Cell-based Therapeutics	
	<i>Dr. Jürgen Meier</i>	914
12.1	To What Extent Are Embryonic Stem Cells Patentable?	915
12.1.1	Are human embryonic stem cells patentable?	917
12.2	Patenting stem cells: facts and summary on most relevant decisions in the EPO. . .	934
12.2.1	Patenting stem cells: T 522/04, “Mammalian multipotent neuronal stem cells/CALIFORNIA INSTITUTE OF TECHNOLOGY”, EP-A1 658 194.	935
12.2.2	Patenting stem cells: T 1199/08, “Selected sperm/XY”	935
12.2.3	Patenting stem cells: T 2221/10, “Culturing stem cells/TECHNION” . . .	937
12.2.4	Patenting stem cells: T 1836/10, “Isolation of embryonic stem cells/WÜRFEL”	940
13.	Patenting Nucleic Acid Amplification Technologies	
	<i>Richard Enmon, Ph.D., J.D.</i>	942
13.1	Clarity (Article 84 EPC).	942
13.1.1	The skilled person knows the limits of relative terms such as “suitable” and “sufficient” in the practice of nucleic acid amplification.	942
13.1.2	Features taught in the disclosure necessary for the practice of the invention are essential features that must be reflected in the claims	948
13.2	Sufficiency of disclosure (Article 83 EPC).	951
13.2.1	T 289/96, “Detecting sequences/ZENECA”, EPB1 332 435.	951
13.2.2	T 965/98, “DNA amplification/HOFFMANN-LA ROCHE”, EPA1 509 612	952
13.2.3	T 216/96, “Process for amplifying, detecting and/or cloning nucleic acid sequences/F. HOFFMANN-LA ROCHE AG”, EPB1 200 362.	952
13.2.4	T 364/06, “Multiplex DNA amplification/BAYLOR”, EPB1 363 255 . . .	955
13.2.5	T 415/07, “Ribosomal display/DISCERNA LTD.”, EPB1 985 032	956
13.2.6	T 2533/10, “Amplification quenched fluorophores primer probes restriction endonuclease recognition site/BECTON DICKENSON”, EPB1 878 554	957
13.2.7	T 842/14, “PCR anti-foam reagents/QIAGEN”, EPB1 1 540 009	958
13.2.8	T 2255/18, “Detection of methicillin-resistant <i>Staphylococcus aureus</i> /GENEOHM SCIENCES CANADA”, EPB1 2 781 604.	959
13.2.9	T 29/19, “Cell free nucleic acids/CNRS”, EPA1 2 611 935.	960
13.3	Novelty (Article 54 EPC)	960
13.3.1	T 902/94, “DNA amplification/BAYLOR COLLEGE OF MEDICINE”, EPA1 364 255	960
13.3.2	T 78/96, “Process for amplifying nucleic acid sequences/F. HOFFMANN-LA ROCHE AG”.	961
13.3.3	T 216/96, “Process for amplifying, detecting and/or cloning nucleic acid sequences/F.HOFFMANN-LA ROCHE AG”, EPB1 200 362.	964

13.3.4	T 445/04, "Homogeneous assay system/F. HOFFMANN-LA ROCHE AG", EPB1 543 942.	965
13.3.5	T 707/03, "Mismatch primer/ZLB BEHRING", EPA1 930 3702	966
13.3.6	T 1091/02, "Methods for detection II/F.HOFFMANN-LA ROCHE AG", EPB1 520 794.	967
13.3.7	T 313/05, "Apparatus for monitoring a polymerase chain reaction/APPLERA", EPB1 872 562	968
13.3.8	T 2050/07, "DNA-Mixture Analysis/PERLIN", EPA1 1 229 135.	969
13.3.9	T 72/10, "Pathogenic organisms/BJÖRN", EPB1 1 254 258.	970
13.3.10	T 2111/09, "Fluorometric method/THE SECRETARY OF STATE FOR DEFENCE", EPB1 1 044 283	971
13.3.11	T 2533/10, "Amplification quenched fluorophores primer probes restriction endonuclease recognition site/BECTON DICKENSON", EPB1 878 554	971
13.3.12	T 2012/10, "Nucleic acid purification/ROCHE DIAGNOSTICS GmbH", EPB1 1 466 018	972
13.3.13	T 1634/15, "CODIS core STR loci forensic human identification/PROMEGA", EPB1 1 135 530	973
13.3.14	T 842/14, "PCR anti-foam reagents/QIAGEN", EPB1 1 540 009	974
13.3.15	T 2042/19, "DNA detection method/DOW AGROSCIENCES", EPA1 2 931 950.	975
13.3.16	T 1608/16, "Detection of MRSA strains/BIOMERIEUX", EPB1 2 231 869.	976
13.4	Inventive Step (Article 56 EPC)	976
13.4.1	T 289/96, "Detecting sequences/ZENECA", EPB1 332 435	976
13.4.2	T 965/98, "DNA amplification/HOFFMANN-LA ROCHE AG", EPA1 509 612; T 966/98, "DNA detection/HOFFMANN-LA ROCHE", EPA1 502 589.	977
13.4.3	T 1118/98, "Nucleic acids/DU Pont De Nemours", EPB1 520 039.	978
13.4.4	T 78/96, "Process for amplifying nucleic acid sequences/F. HOFFMANN-LA ROCHE AG", EPB1 201 184	978
13.4.5	T 216/96, "Process for amplifying, detecting and/or cloning nucleic acid sequences/F. Hoffmann-La Roche AG", EPB1 200 362	979
13.4.6	T 302/02, "Automated amplification/APPLERA", EPB1 236 069	980
13.4.7	T 239/01, "Coupled transcription and translation/PROMEGA", EPB1 566 714.	980
13.4.8	T 707/03, "Mismatch primer/ZLB BEHRING", EPA1 930 370.	981
13.4.9	T 445/04, "Homogeneous assay system/F.HOFFMANN-LA ROCHE AG", EPB1 543 942.	982
13.4.10	T 1091/02, "Methods for detection II/F.HOFFMANN-LA ROCHE AG", EPB1 520 794.	983
13.4.11	T 781/06, "Amplification of nucleic acids/SANOFI-AVENTIS", EPA1 829 542.	983
13.4.12	T 531/05, "Extracellular tumor-associated nucleic acid/PENN STATE RESEARCH FOUNDATION", EPA1 929 694	983
13.4.13	T 768/06, "Molecular evolution/MAXYGEN", EPB1 876 509	984
13.4.14	T 415/07, "Ribosomal display/DISCERNA LTD.", EPB1 985 032.	985
13.4.15	T 1739/07, "Addressable array/CORNELL RESEARCH FOUNDATION", EPA1 920 440.	985
13.4.16	T 1958/09, "Elonas/GILEAD", EP A1 832 291.	986

13.4.17	T 1588/10, "Detection Japanese encephalitis viruses/ROCHE", EPA1 1 611 254	987
13.4.18	T 2264/09, "Multiplex amplification of STRs/PROMEGA", EP B1 960 207	988
13.4.19	T 2012/10, "Nucleic acid purification/ROCHE DIAGNOSTICS GmbH", EPB1 1 466 018	989
13.4.20	T 1631/10, "Magnetische Partikel/ROCHE", EPB1 1 577 349	989
13.4.21	T 14/12, "Emulsion asymmetric PCR-pre-hybridisation single stran- ded template immobilized primer bead/454 LIFE SCIENCES", EPB1 1 594 980	990
13.4.22	T 300/13 "Noro Virus/BML INC", EPB1 1 329 522	991
13.4.23	T 1119/12, "Orthogonal oligonucleotides/SIEMENS HEALTHCARE DIAGNOSTICS", EPA1 1 844 163	992
13.4.24	T 1904/16, "Assay for toxinogenic C. difficile strains/KONINKLIJKE PHILLIPS", EPB1 2 419 527	993
13.4.25	T 2042/19, "DNA detection method/DOW AGROSCIENCES", EPA1 2 931 950	995
13.4.26	T 2255/18, "Detection of methicillin-resistant Staphylococcus aureus/ GENEOHM SCIENCES CANADA", EPB1 2 781 604	996
14.	Patenting Genome Editing Technologies: CRISPR et al.	
	<i>Dr. Andreas Heiseke</i>	997
14.1	History of Genome Editing Technologies	997
14.2	Genome Editing with Meganucleases	998
14.3	Genome Editing with Zinc Finger Nucleases (ZFNs)	998
14.4	Genome Editing with Transcription Activator-Like Effector Nucleases (TALENs)	999
14.5	Genome Editing with CRISPR-Cas9	1000
14.6	Patenting the Genome Editing Technologies Meganucleases, ZFNs and TALENs in the EPO	1002
14.7	Patenting the Genome Editing Technology CRISPR-Cas9 in the EPO	1008
15.	Patenting Next Generation Sequencing Technologies	
	<i>Dr. Florian Grasser</i>	1023
15.1	History of NGS	1023
15.2	Current state of the art of NGS	1023
15.3	Market potential and future perspective of NGS	1025
15.4	Decisions of the Technical Boards of Appeal relating to NGS	1025
16.	Patenting Personalized Medicines and Companion Diagnostics	
	<i>Dr. Christian Schlörb</i>	1055
16.1	Introduction	1055
16.2	Exclusion from patentability	1055
	16.2.1 T 1038/00, "Apoptotic cells/NEXINS RESEARCH", EP-B1 755 516	1055
	16.2.2 T 310/99, "Down Syndrome/MACRI", EP-B1 409 956	1055
	16.2.3 T 2050/07, "DNA Mixture Analysis/PERLIN", EP-A1 1 229 135	1056
	16.2.4 T 606/96, "Radiolabelled antibodies/RHOMED INC.", EP-B1 234 612	1056
16.3	Novelty	1057
	16.3.1 Introduction	1057

16.3.2	T 734/12 “, Arthritis patients with an inadequate response to a TNF-alpha inhibitor/GENENTECH, INC.”, EP-B1 1 613 350.....	1057
16.3.3	T 1399/04, “Combination therapy HCV/SCHERING”, EP-B1 956 861 ..	1058
16.3.4	T 694/16, “Food Composition for Prodromal Dementia Patients/ NUTRICIA”, EP-B1 2 170 104	1058
16.3.5	T 108/09, “Fulvestrant for treating resistant breast cancer/ASTRA ZENECA AB”, EP-B1 1 272 195	1059
16.4	Inventive step	1059
16.4.1	T 777/17, “Degarelix in metastatic stage prostate cancer/FERRING”, EPA2 2 249 859.....	1059
16.4.2	T 967/16, “Oxcarbazepine Stevens-Johnson Syndrome/ACADEMIA SINICA PHARMIGENE”, EPB1 2 016 198	1060
16.4.3	T 2197/10, “APRIL Receptor/BIOGEN”, EPB1 1 223 964	1060
16.5	Clarity	1061
16.5.1	T 241/95, “Serotonin receptor/ELI LILLY”, EP-A2 0 449 562	1061
16.5.2	Decision of the Opposition Division on EP-B1 785 216 (September 12, 2005) and T 156/08, “BRCA2/UNIVERSITY OF UTAH”, EP-A1 1 260 520.....	1061
16.5.3	T 1845/11, “Asian race/MERCK SERONO”, EP-A1 1 509 242.....	1062
16.6	Sufficiency of disclosure	1062
16.6.1	T 1031/09, “GST-Pi gene/COMMONWEALTH”, EP-A1 1 071 815 ...	1062
16.6.2	T 734/12 “, Arthritis patients with an inadequate response to a TNF-alpha inhibitor/GENENTECH, INC.”, EP-B1 1 613 350.....	1063
16.6.3	T 1474/12, “Diagnostic marker/ANTIBODYSHOP”, EP-B1 1 831 699. . .	1065
16.6.4	T 50/10, “BCRP/University of Maryland”, EP-B1 1 054 894	1065
17.	Patenting Plants and Animals	
	<i>Dr. Olaf Malek</i>	1067
17.1	Exceptions to patentability (Article 53(a) and (b) EPC)	1067
17.1.1	Ordre public and morality (Article 53(a) EPC)	1067
17.1.2	Exclusions with respect to plants (Article 53(b) EPC)	1070
17.1.3	Exclusions with respect to animals (Article 53(b) EPC)	1087
17.2	Clarity and support in the description (Article 84 EPC).....	1090
17.2.1	Definition by reference to species	1090
17.2.2	Definition by reference to genetic markers	1090
17.2.3	Product-by process definition	1091
17.2.4	Clarity and support	1094
17.3	Sufficiency (Article 83 EPC).....	1098
17.3.1	Fair balance between claimed scope and the invention’s contribution.	1098
17.3.2	Functional features	1102
17.3.3	Evidence required for denying enablement.....	1103
17.3.4	Undue burden/research project.....	1106
17.3.5	Effect plausibly disclosed in application/Example sufficient	1109
17.3.6	Elite event.....	1111
17.3.7	Starting material	1112
17.3.8	Screening required for carrying out the invention.....	1114
17.4	Novelty (Article 54 EPC)	1115
17.4.1	Public availability (including database entries and internet disclosure)	1115
17.4.2	Meaning of terms	1116
17.4.3	Is the prior art enabling?.....	1118

17.4.4	Feature combination directly and unambiguously derivable	1121
17.4.5	Whole contents approach	1123
17.4.6	Anticipation of compound claims	1125
17.4.7	Composition of chemical compounds made available	1125
17.4.8	Inherency	1126
17.4.9	Inevitable result of carrying out a process	1127
17.4.10	Denial of novelty requires certainty	1132
17.5	Inventive step (Article 56 EPC)	1133
17.5.1	Selection of the closest prior art	1133
17.5.2	Technical problem to reflect actual contribution	1135
17.5.3	Surprising advantageous effect	1138
17.5.4	No incentive	1139
17.5.5	Obviousness when the prior art guides to exactly the claimed feature combination	1143
17.5.6	For obviousness, the prior art does not always have to guide to exactly the claimed feature combination	1154
17.5.7	Technical differences between plants and other kingdoms of life	1158
17.5.8	Reasonable expectation of success	1158
17.5.9	Claims to “elite events”	1163
17.5.10	Try-and-see	1166
17.5.11	Avoid ex post facto analysis	1167
17.5.12	Non-obvious alternative	1168
17.5.13	Technical difficulties overcome in non-obvious way	1171
18.	Priority – Hurdles of Same Subject Matter and Legal Entitlement	
	<i>Dr. Olaf Malek</i>	1174
18.1	The “same invention” hurdle	1174
18.1.1	Direct and unambiguous disclosure	1174
18.1.2	Enablement	1202
18.1.3	Plausibility	1212
18.1.4	The first application (Article 87(1) and (4) EPC)	1215
18.2	The “legal entitlement” hurdle	1216
18.2.1	The original priority right	1217
18.2.2	The priority right obtained as successor in title	1219
18.3	Other priority matters	1222
18.3.1	Exhaustion of priority right	1222
18.3.2	Deviating priority documents in official file	1223
18.3.3	Exhibition priority	1223
19.	Deposit	
	<i>Dr. Stefan Müller</i>	1225
19.1	General principles developed in biotech cases and the legal basis	1225
19.2	Procedural law questions	1227
19.2.1	Information with regard to the biological material and the deposit to be given in the application	1227
19.2.2	Information with regard to the biological material in case of a deposit by a person other than the Applicant	1229
19.2.3	Choice of the expert solution under Rule 32 EPC	1230

19.3	Substantial law questions/Decision dealing with the time limit in context with a deposition of biological material	1231
19.4	Substantial law questions/Case Law dealing with the question whether the reproducibility of biological material was assured by the written description in the absence of a deposit	1234
20.	How to draft a European Patent Application and Claims <i>Dr. Philipp Marchand</i>	1243
20.1	The European Patent Application	1243
20.2	How to file a European patent application (Article 75 EPC)	1243
20.3	Requirements for a European Patent Application	1245
20.3.1	Request for grant	1245
20.3.2	Description.	1246
20.3.3	Drawings and Legends to Figures	1248
20.3.4	Examples of the Invention	1249
20.3.5	The Claims	1250
20.3.6	The Abstract	1251
20.4	Minimal Requirements to Obtain a Filing Date	1251
20.5	Content of a European patent application	1253
20.5.1	Sufficiency of Disclosure.	1253
20.5.2	Clarity and Support	1254
20.5.3	Sequence Listings	1255
20.5.4	Deposits	1257
21.	A Brief Introduction to Supplementary Protection Certificates <i>Oswin Ridderbusch</i>	1259
21.1	Introduction.	1259
21.2	Territorial Availability of SPCs in Europe	1259
21.3	Subject-matter of an SPC	1260
21.4	Conditions for Obtaining an SPC	1260
21.4.1	Basic Patent	1260
21.4.2	Marketing Authorization	1261
21.4.3	Only the First Marketing Authorization Allows the Filing of an SPC	1262
21.4.4	Multiple SPCs for Different Products Based on a Single Patent	1262
21.4.5	Multiple SPCs for the Same Product	1262
21.4.6	Relationship between the SPC Applicant and the Holder of the Marketing Authorization	1262
21.5	Scope of Protection.	1263
21.6	Time Limit for Filing an SPC	1264
21.7	SPC Term.	1264
21.8	Paediatric Extensions of SPCs.	1265
22.	Biotech Litigation In Germany And The Netherlands, Perspectives Arising From The Implementation Of The UPC <i>Daan de Lange, Dr. Kai Rüting</i>	1267
22.1	Introduction.	1267
22.2	Overview on Patent Litigation in Germany, the Netherlands and the UPC	1269
22.2.1	Characteristics of Patent Litigation in Germany	1269

22.2.2	Patent Litigation in the Netherlands	1270
22.2.3	Patent Litigation before the UPC	1271
22.3	Scope of Protection.	1272
22.3.1	Determination of the Scope of Protection in Germany.	1273
22.3.2	Determination of the Scope of Protection in the Netherlands	1277
22.3.3	Determination of the Scope of Protection before the UPC.	1280
22.4	Direct Infringement	1281
22.4.1	Product Claims.	1282
22.4.2	Process Claims	1288
22.4.3	Products Made by an Infringing Process.	1290
22.4.4	Indirect Infringement	1293
22.5	Second Medical Use Patents	1296
22.5.1	Enforcement of Second Medical Use Patents in Germany	1297
22.5.2	Enforcement of Second Medical Use Claims in the Netherlands	1300
22.5.3	Enforcement of Second Medical Use Claims at the UPC.	1300
22.6	Limitations to the Exclusive Rights of the Patentee.	1300
22.6.1	Experimental Use Exemption	1301
22.6.2	Bolar Exemption	1302
22.7	Pharmacist Exemption	1305
22.8	Proving of the Case and Evidence Collection	1305
22.8.1	Burden of Proof	1305
22.8.2	Production of Evidence/Request for Disclosure	1308
22.9	Remedies	1310
22.9.1	Overview on Remedies.	1310
22.9.2	Preliminary Injunctions	1310
22.9.3	Permanent Injunctions and Proportionality Defense	1316
22.9.4	Recall and Destruction.	1320
22.9.5	Rendering of Account.	1321
22.9.6	Damages.	1321
22.9.7	Cost of the Proceedings	1322
	Decisions of the EPO	1325
	Index	1403